TAVI in Intermediate Risk Septuagenarians With Risk Factors Not Captured by the Traditional Surgical Risk Scores

Study Overview
=================
Brief Summary
-----------------
Single arm, observational trial of Transcatheter Aortic Valve Implantation (TAVI) with the Medtronic Evolut R and Evolut Pro The primary objective of this trial is to evaluate device success of TAVI with the Evolut R and Evolut Pro systems in septuagenarians with risk factors for adverse surgical outcomes not captured by the traditional risk scores and therefore of intermediate surgical risk.

Detailed Description
-----------------
The purpose of this study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in septuagenarians with severe, symptomatic Aortic Stenosis (AS) and risk factors for adverse surgical outcomes not captured by the traditional risk scores and therefore of intermediate surgical risk. The primary objective of this trial is to evaluate device success of TAVI with the Evolut R and Evolut Pro systems in septuagenarians with risk factors for adverse surgical outcomes not captured by the traditional risk scores and therefore of intermediate surgical risk. The secondary objective is to assess early safety (at 30 days) and clinical efficacy (after 30 days) of the TAVI procedure. Exploratory objective: comparative health economics in septuagenarians with symptomatic severe aortic stenosis and intermediate surgical risk treated with Transcatheter Aortic Valve Implantation (TAVI) vs Surgical Aortic Valve Replacement (SAVR) (matched historic cohort)

Official Title
-----------------
TAVI in Intermediate Risk Septuagenarians With Risk Factors Not Captured by the Traditional Surgical Risk Scores

Conditions
-----------------
Transcatheter Aortic Valve Replacement

Intervention / Treatment
-----------------
* Device: Transcatheter Aortic Valve Implantation (TAVI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 75-79 Subject must have Society of Thoracic Surgeons (STS) score >=4% and <=8% Subject must have at least one from the risk factors presented below: i. Severely atherosclerotic or porcelain aorta ii. Internal Mammary Artery (IMA) or other conduit(s) crossing midline and/or adherent to posterior table of sternum iii. Pre-existing mechanical valve in any other position iv. Severe right ventricular dysfunction v. Hostile chest (abnormal chest wall anatomy due to severe kyphoscoliosis or other skeletal abnormalities, evidence of severe radiation damage, history of multiple recurrent pleural effusions causing internal adhesions) vi. Severe liver disease/cirrhosis vii. Frailty viii. Malignancy with life expectancy that exceeds 24 months ix. Renal replacement therapy with creatinine levels >200mmol/L or 2.26 mg/dl Heart team consisting of at least one interventional cardiologist and one cardiac surgeon agree on indication and treatment proposal, based on their clinical judgment (including anatomy assessment, risk factors, etc) Critical aortic valve area defined as an initial aortic valve area of <=1cm2 or aortic valve index <0.6cm2/m2 In presence of normal left ventricular function: Mean gradient >40mmHg OR Vmax>4m/sec OR In presence of low flow, low gradient severe AS, a dobutamine stress echo must be conducted that demonstrates presence of contractile reserve defined as follows >=20% increase in stroke volume and mean gradient >40mmHg Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by New York Heart Association (NYHA) Functional Class II or greater The subject is suitable for direct TAVI not preceded by balloon valvuloplasty according to the judgment of the treating physicians The subject and the treating physician agree that the subject will return for all required post procedure follow-up visits. Exclusion Criteria: Hypersensitivity or contraindication to aspirin, heparin, clopidogrel, coumadin, nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated; Blood dyscrasias as defined: leukopenia (WBC<1000/mm3), thrombocytopenia (platelet count <50.000cells/mm3), history of bleeding diathesis or coagulopathy; Ongoing sepsis, including active endocarditis Any condition considered a contraindication to extracorporeal assistance; Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within six weeks prior treatment Cardiogenic shock manifested by low cardiac output, vasopressor dependence or mechanical hemodynamic support; Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA) Active gastrointestinal (GI) bleeding within the past 3 months Subject refuses a blood transfusion; Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits); Multivessel coronary artery disease with a Syntax score >22 Estimated life expectancy of less than 24 months due to associated non-cardiac comorbid conditions Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consentor adherence to the protocol required follow-up exams; Currently participating in an investigational drug or another device trial (excluding registries) Evidence of an acute myocardial infarction <=30 days before the index procedure Need for emergency surgery for any reason Uncontrolled atrial fibrillation Anatomical Exclusion Criteria: Native aortic annulus size <18mm or >30mm per the baseline diagnostic imaging; Mixed aortic valve disease [aortic stenosis and aortic regurgitation with predominant aortic regurgitation (3-4+] Severe mitral or severe tricuspid regurgitation Severe mitral stenosis; Hypertrophic obstructive cardiomyopathy Echocardiographic or Multislice Computed Tomography (MSCT) evidence of intracardiac mass, thrombus or vegetation Anatomy of the aortic root and ascending aorta not suitable for TAVI with Evolut R or Evolut Pro system (aortic root angulation >70 degrees for femoral and left subclavian access or >30 degrees for right subclavian access) Congenital bicuspid or unicuspid valve verified by echocardiography Vascular Exclusion Criteria Transarterial access not able to accommodate an 16 French sheath

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Transcatheter Aortic Valve Implantation (TAVI)|Transcatheter Aortic Valve Implantation with Evolut R or Evolut Pro|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Device success (VARC-2 criteria) | Absence of procedural mortality Correct positioning of the prosthetic heart valve into the proper anatomical location Intended performance of the prosthetic heart valve (mean aortic valve gradient<20mmHg or peak velocity < 3m/s, and no moderate or severe prosthetic valve regurgitation) as assessed with 24h post implantation and pre-discharge echocardiogram | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of All-cause mortality | Early Safety | 30 days | 
| Rate of All stroke (disabling and non-disabling) | Early Safety | 30 days | 
| Rate of Life-threatening bleeding | Early Safety | 30 days | 
| Rate of Acute Kidney Injury-Stage 2 or 3 (including renal replacement therapy) | Early Safety | 30 days | 
| Rate of Coronary artery obstruction requiring intervention | Early Safety | 30 days | 
| Rate of Major vascular complication | Early Safety | 30 days | 
| Rate of Valve-related dysfunction requiring repeat procedure (BAV, TAVI or SAVR) | Early Safety | 30 days | 
| Rate of New pacemaker implantation | Early Safety | 30 days | 
| Rate of All-cause mortality | Clinical Efficacy | after 30 days and up to 2 years | 
| Rate of All stroke (disabling and non-disabling) | Clinical Efficacy | after 30 days and up to 2 years | 
| Rate of Hospitalizations for valve-related symptoms or worsening congestive heart failure NYHA class III or IV | Clinical Efficacy | after 30 days and up to 2 years | 
| Rate of Valve related dysfunction | Mean aortic valve gradient >=20mmHg, Effective orifice area (EOA)<=0.9-1.1cm2, and/or Dimensionless Valve Index (DVI)<0.35 m/s and/or moderate or severe prosthetic valve regurgitation | after 30 days and up to 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aortic stenosis, TAVI, Evolut R, Evolut Pro